XXII 22nd Century Group Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: XXII

Price (delayed)

$1.735

Market cap

$6.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$116.48

Enterprise value

$20.36M

22nd Century is a plant biotechnology company focused on technology which allows it to decrease the level of nicotine in tobacco plants and modify the levels of cannabinoids in hemp/cannabis ...

Highlights
The debt has contracted by 40% from the previous quarter
22nd Century Group's EPS has plunged by 57% YoY but it has increased by 11% from the previous quarter
The company's gross margin has shrunk by 200% QoQ
The company's equity has shrunk by 161% QoQ and by 109% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.xxiicentury.com
Peers: PM MO VGR

Key stats

What are the main financial stats of XXII
Market
Shares outstanding
3.48M
Market cap
$6.04M
Enterprise value
$20.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.63
Earnings
Revenue
$32.2M
EBIT
-$131.36M
EBITDA
-$126.5M
Free cash flow
-$59.36M
Per share
EPS
-$116.48
Free cash flow per share
-$45.86
Book value per share
-$4.36
Revenue per share
$24.88
TBVPS
$16.67
Balance sheet
Total assets
$27.5M
Total liabilities
$35.91M
Debt
$16.38M
Equity
-$8.41M
Working capital
-$8.76M
Liquidity
Debt to equity
-1.95
Current ratio
0.65
Quick ratio
0.23
Net debt/EBITDA
-0.11
Margins
EBITDA margin
-392.8%
Gross margin
-27%
Net margin
-437.1%
Operating margin
-139.5%
Efficiency
Return on assets
-176.9%
Return on equity
-378.5%
Return on invested capital
-319.5%
Return on capital employed
-5,320.5%
Return on sales
-407.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XXII stock price

How has the 22nd Century Group stock price performed over time
Intraday
-5.19%
1 week
7.1%
1 month
-17.48%
1 year
141.88%
YTD
831.79%
QTD
-9.64%

Financial performance

How have 22nd Century Group's revenue and profit performed over time
Revenue
$32.2M
Gross profit
-$8.7M
Operating income
-$44.93M
Net income
-$140.78M
Gross margin
-27%
Net margin
-437.1%
The company's gross margin has shrunk by 200% QoQ
The net margin has plunged by 196% YoY and by 93% from the previous quarter
The net income has dropped by 135% year-on-year and by 2.2% since the previous quarter
The operating margin has plunged by 68% YoY but it has grown by 22% from the previous quarter

Growth

What is 22nd Century Group's growth rate over time

Valuation

What is 22nd Century Group stock price valuation
P/E
N/A
P/B
N/A
P/S
0.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.63
22nd Century Group's EPS has plunged by 57% YoY but it has increased by 11% from the previous quarter
The company's equity has shrunk by 161% QoQ and by 109% YoY
The price to sales (P/S) is 99% lower than the 5-year quarterly average of 8.2 and 94% lower than the last 4 quarters average of 1.2
The revenue fell by 47% QoQ and by 20% YoY

Efficiency

How efficient is 22nd Century Group business performance
22nd Century Group's ROS has plunged by 177% YoY and by 87% from the previous quarter
22nd Century Group's ROE has plunged by 80% from the previous quarter
The ROIC has contracted by 49% from the previous quarter
The company's return on assets fell by 36% QoQ

Dividends

What is XXII's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XXII.

Financial health

How did 22nd Century Group financials performed over time
22nd Century Group's total assets is 23% less than its total liabilities
The total liabilities has soared by 92% YoY but it has contracted by 29% from the previous quarter
The company's quick ratio has shrunk by 86% YoY and by 45% QoQ
XXII's debt to equity has shrunk by 199% QoQ
The company's equity has shrunk by 161% QoQ and by 109% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.